4-aminobenzoic acid has been researched along with Neoplasms in 24 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose-limiting toxicities were nausea/vomiting and myelosuppression; myelosuppression was more frequent with QD dosing and associated with pharmacokinetic exposure." | 3.01 | Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. ( Bang, YJ; Blay, JY; Blotner, S; Chen, LC; Gietema, JA; Higgins, B; Hirte, HW; Italiano, A; Jamois, C; Mileshkin, LR; Miller, WH; Nichols, GL; Petry, C; Schmitt, C; Siu, LL; Yang, QJ, 2021) |
| " Methods Patients were evaluated on a 5-day dosing schedule every 28 days." | 2.94 | A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. ( Abdul Razak, AR; Blotner, S; Chen, LC; Gore, L; Higgins, B; Miller, WH; Uy, GL; Young, AM, 2020) |
| "In patients with lung cancer, tankyrase levels negatively correlate with p-AMPK levels and poor survival." | 1.51 | Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. ( Chen, J; Chen, Z; Deng, W; Fong, LWR; Hung, MC; Jiang, W; Li, N; Li, X; Lin, SH; Neri, S; Qiao, Y; Stephan, C; Wang, Y; Ye, R; Yu, Y; Zhang, S; Zhen, Y, 2019) |
| "A total of 69 patients who have both idasanutlin pharmacokinetic data and UGT genotyping data were analyzed for association." | 1.51 | Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients. ( Ou Yang, TH; So, WV; Yang, X; Zhi, J, 2019) |
| "This was an open-label, single-dose, crossover clinical pharmacology study investigating the effects of strong CYP3A4 inhibition with posaconazole (Part 1), two new oral formulations (Part 2), as well as high-energy/high-fat and low-energy/low-fat meals (Part 3) on the relative bioavailability of idasanutlin." | 1.48 | Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. ( Blotner, S; Chen, LC; Ejadi, S; Miller, W; Nemunaitis, J; Nichols, G; Razak, A; Vazvaei, F; Young, A; Zhi, J, 2018) |
| "The rapid proliferation of cancer cells mandates a high protein turnover." | 1.35 | Nitrosative stress-induced s-glutathionylation of protein disulfide isomerase leads to activation of the unfolded protein response. ( Bowers, RR; He, L; Hutchens, S; Manevich, Y; Tew, KD; Townsend, DM; Xiong, Y, 2009) |
| " Including one patient receiving a high dosage (over 200 g totally) of K-247, in all cases, no appreciable side effect causing suspension of the administration was recognized." | 1.26 | [Clinical trial of K-247]. ( Kakuta, H; Kanamaru, R; Kanbe, M; Mitachi, Y; Sato, T; Takahashi, K; Wakui, A, 1982) |
| "Eleven patients with a variety of solid tumors were treated with K-247 alone." | 1.26 | [Antitumor effects of p-aminobenzoic acid-N-xyloside Na--effects of single administration and combination with radiotherapy]. ( Fukushima, M; Ota, K, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (20.83) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, N | 1 |
| Wang, Y | 1 |
| Neri, S | 1 |
| Zhen, Y | 1 |
| Fong, LWR | 1 |
| Qiao, Y | 1 |
| Li, X | 1 |
| Chen, Z | 1 |
| Stephan, C | 1 |
| Deng, W | 1 |
| Ye, R | 1 |
| Jiang, W | 1 |
| Zhang, S | 1 |
| Yu, Y | 1 |
| Hung, MC | 1 |
| Chen, J | 1 |
| Lin, SH | 1 |
| Chen, K | 1 |
| Xin, X | 1 |
| Qiu, L | 1 |
| Li, W | 1 |
| Guan, G | 1 |
| Li, G | 1 |
| Qiao, M | 1 |
| Zhao, X | 1 |
| Hu, H | 1 |
| Chen, D | 1 |
| Abdul Razak, AR | 1 |
| Miller, WH | 2 |
| Uy, GL | 1 |
| Blotner, S | 5 |
| Young, AM | 1 |
| Higgins, B | 3 |
| Chen, LC | 5 |
| Gore, L | 1 |
| Duffy, MJ | 1 |
| Synnott, NC | 1 |
| O'Grady, S | 1 |
| Crown, J | 1 |
| Tezcan, G | 1 |
| Garanina, EE | 1 |
| Alsaadi, M | 1 |
| Gilazieva, ZE | 1 |
| Martinova, EV | 1 |
| Markelova, MI | 1 |
| Arkhipova, SS | 1 |
| Hamza, S | 1 |
| McIntyre, A | 1 |
| Rizvanov, AA | 1 |
| Khaiboullina, SF | 1 |
| Italiano, A | 1 |
| Blay, JY | 1 |
| Gietema, JA | 1 |
| Bang, YJ | 1 |
| Mileshkin, LR | 1 |
| Hirte, HW | 1 |
| Nichols, GL | 1 |
| Petry, C | 1 |
| Yang, QJ | 1 |
| Schmitt, C | 1 |
| Jamois, C | 1 |
| Siu, LL | 1 |
| Nemunaitis, J | 1 |
| Young, A | 1 |
| Ejadi, S | 1 |
| Miller, W | 1 |
| Nichols, G | 1 |
| Vazvaei, F | 2 |
| Zhi, J | 4 |
| Razak, A | 1 |
| Ferlini, C | 1 |
| So, WV | 1 |
| Ou Yang, TH | 1 |
| Yang, X | 1 |
| Pápai, Z | 1 |
| Da Costa, D | 1 |
| Gleave, M | 1 |
| Jones, R | 1 |
| Ungermannova, D | 1 |
| Lee, J | 1 |
| Zhang, G | 1 |
| Dallmann, HG | 1 |
| McHenry, CS | 1 |
| Liu, X | 1 |
| Suresh, DM | 1 |
| Amalanathan, M | 1 |
| Joe, IH | 1 |
| Jothy, VB | 1 |
| Diao, YP | 1 |
| Zhang, Z | 1 |
| Ding, Q | 1 |
| Liu, JJ | 1 |
| Zhang, J | 1 |
| Jiang, N | 1 |
| Chu, XJ | 1 |
| Bartkovitz, D | 1 |
| Luk, KC | 1 |
| Janson, C | 1 |
| Tovar, C | 1 |
| Filipovic, ZM | 1 |
| Glenn, K | 1 |
| Packman, K | 1 |
| Vassilev, LT | 1 |
| Graves, B | 1 |
| Zhang, B | 1 |
| Golding, BT | 1 |
| Hardcastle, IR | 1 |
| Esfandiari, A | 1 |
| Hawthorne, TA | 1 |
| Nakjang, S | 1 |
| Lunec, J | 1 |
| Yu, N | 1 |
| Wang, M | 1 |
| Townsend, DM | 2 |
| Manevich, Y | 1 |
| He, L | 1 |
| Xiong, Y | 1 |
| Bowers, RR | 1 |
| Hutchens, S | 1 |
| Tew, KD | 2 |
| CURTIS, GH | 1 |
| CRAWFORD, PF | 1 |
| Findlay, VL | 1 |
| Teuscher, E | 1 |
| Pester, E | 1 |
| Saleh, AM | 1 |
| Pheasant, AE | 1 |
| Blair, JA | 1 |
| Allan, RN | 1 |
| Walters, J | 1 |
| Kanamaru, R | 1 |
| Takahashi, K | 1 |
| Mitachi, Y | 1 |
| Kanbe, M | 1 |
| Sato, T | 1 |
| Kakuta, H | 1 |
| Wakui, A | 1 |
| Fukushima, M | 1 |
| Ota, K | 1 |
| Ohshio, G | 1 |
| Tanaka, T | 1 |
| Imamura, T | 1 |
| Okada, N | 1 |
| Yoshitomi, S | 1 |
| Suwa, H | 1 |
| Hosotani, R | 1 |
| Imamura, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Mali[NCT02098967] | Phase 1 | 68 participants (Actual) | Interventional | 2014-04-21 | Completed | ||
| A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia[NCT01462175] | Phase 1 | 99 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for 4-aminobenzoic acid and Neoplasms
| Article | Year |
|---|---|
Targeting p53 for the treatment of cancer.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Cycle Proteins; Humans; Neoplasms; para-Aminobenzoates; | 2022 |
Small-molecule MDM2-p53 inhibitors: recent advances.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Crystallography, X-Ray; Humans; Imidazoles | 2015 |
Anticancer drug discovery targeting DNA hypermethylation.
Topics: 4-Aminobenzoic Acid; Adenosine; Animals; Antineoplastic Agents; Cytidine; DNA (Cytosine-5-)-Methyltr | 2008 |
Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Agents; Azo Compounds; Cisplatin; Cytotoxins; Drug Comb | 2005 |
4 trials available for 4-aminobenzoic acid and Neoplasms
| Article | Year |
|---|---|
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Growth Differen | 2020 |
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2021 |
Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Electrocardiography | 2018 |
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Cohort Studies; D | 2019 |
16 other studies available for 4-aminobenzoic acid and Neoplasms
| Article | Year |
|---|---|
Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Carcinogenesis; Cell L | 2019 |
Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Body Weight; Cell Cycle Checkpoints; Cell Line, Tumor; Cell M | 2019 |
Therapeutic Potential of Pharmacological Targeting NLRP3 Inflammasome Complex in Cancer.
Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cytokines; Dipeptides; Humans; | 2020 |
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Topics: Administration, Oral; Area Under Curve; Biological Availability; Cross-Over Studies; Cytochrome P-45 | 2018 |
Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients.
Topics: Glucuronosyltransferase; Humans; Neoplasms; para-Aminobenzoates; Polymorphism, Single Nucleotide; Pr | 2019 |
High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.
Topics: Benzoates; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase Inhibitor p27; Drug Screening Assays, Antitum | 2013 |
Studies on molecular structure, vibrational spectra and molecular docking analysis of 3-Methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl 4-aminobenzoate.
Topics: Crystallization; Hydrogen Bonding; Molecular Conformation; Molecular Docking Simulation; Naphthoquin | 2014 |
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
Topics: Apoptosis; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Humans | 2014 |
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Catalysis; Cell Line, Tumor; | 2016 |
Nitrosative stress-induced s-glutathionylation of protein disulfide isomerase leads to activation of the unfolded protein response.
Topics: 4-Aminobenzoic Acid; Amino Acid Sequence; Azo Compounds; Catalytic Domain; Cell Line, Tumor; Cystein | 2009 |
Cutaneous sensitivity to monoglycerol para-aminobenzoate; cross sensitization and bilateral eczematization; report of a second case.
Topics: 4-Aminobenzoic Acid; Dermatitis, Contact; Humans; Lung Neoplasms; Neoplasms; Nervous System Physiolo | 1951 |
A possible explanation of mechanisms inducing inhibition of vascularization of tumours by antifibrinolytic drugs--the influence of migratory behaviour of endothelial cells.
Topics: 4-Aminobenzoic Acid; Animals; Antifibrinolytic Agents; Aorta; Aprotinin; Cell Line; Cell Movement; C | 1984 |
Folate metabolism in man: the effect of malignant disease.
Topics: 4-Aminobenzoic Acid; Adolescent; Aged; Feces; Female; Folic Acid; Glutamates; Humans; Male; Middle A | 1982 |
[Clinical trial of K-247].
Topics: 4-Aminobenzoic Acid; Adult; Aged; Aminobenzoates; Antineoplastic Agents; Breast Neoplasms; Female; H | 1982 |
[Antitumor effects of p-aminobenzoic acid-N-xyloside Na--effects of single administration and combination with radiotherapy].
Topics: 4-Aminobenzoic Acid; Adult; Aged; Aminobenzoates; Antineoplastic Agents; Drug Evaluation; Female; Hu | 1982 |
Exocrine pancreatic function in the early period after pancreatoduodenectomy and effects of preoperative pancreatic duct obstruction.
Topics: 4-Aminobenzoic Acid; Amylases; Constriction, Pathologic; Female; Humans; Lipase; Male; Middle Aged; | 1996 |